APLIF OTC
Appili Therapeutics Inc
1W: -22.2%
1M: +0.0%
3M: -34.5%
YTD: -53.3%
1Y: -50.0%
3Y: -82.5%
5Y: -98.8%
$0.01
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$245K
+143.7% ▲
Gross Profit
$237K
+135.7% ▲
Operating Income
-$7M
-3332.3% ▼
Net Income
-$4M
-62.0% ▼
EPS (Diluted)
$-0.03
-59.3% ▼
EBITDA
-$7M
-1914.4% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $1M | $334K | $827K | $100K | $245K |
| YoY Growth | +0.0% | -76.0% | +147.6% | -87.9% | +143.7% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $8K |
| Gross Profit | $1M | $334K | $827K | $100K | $237K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 96.7% |
| R&D Expenses | $21M | $4M | $6M | $7M | $4M |
| SG&A Expenses | $5M | $4M | $3M | $3M | $2M |
| Operating Expenses | $25M | $8M | $3M | $291K | $7M |
| Operating Income | -$24M | -$8M | -$2M | -$191K | -$7M |
| Operating Margin | -1698.1% | -2326.9% | -261.4% | -190.0% | -2675.6% |
| Interest Expense | $2M | $1M | $2M | $3M | $1M |
| Income Before Tax | -$25M | -$9M | -$4M | -$3M | -$4M |
| Tax Expense | $38K | $36K | $70K | $19K | $97K |
| Net Income | -$25M | -$9M | -$4M | -$3M | -$4M |
| Net Margin | -1806.2% | -2765.9% | -457.0% | -2613.1% | -1736.7% |
| EPS (Diluted) | $-0.38 | $-0.08 | $-0.03 | $-0.02 | $-0.03 |
| EBITDA | -$24M | -$8M | -$2M | $361K | -$7M |
| Shares Outstanding | 67M | 114M | 121M | 121M | 124M |